KMT2A and acute lymphoblastic leukemia: Similar to GNF2133, harmine treatment in combination with venetoclax led to a significant reduction in KMT2A-R ALL in mice, thereby validating our findings and underscoring DYRK1A’s critical role in KMT2A-R ALL (data not shown).